- The research demonstrates that specific, human microbiome-derived bacteria assembled rationally into consortia can cooperatively enhance the responses to immune checkpoint inhibitors
- Based on this research, Vedanta is advancing VE800, a proprietary clinical candidate designed to enhance immune responses against cancer.
- Vedanta plans to initiate clinical studies in 2019
